Venous Thromboembolism and Renal Impairment: Insights from the SWIss Venous ThromboEmbolism Registry (SWIVTER)

David Spirk; Tim Sebastian; Martin Banyai; Jürg H. Beer; Lucia Mazzolai; Thomas Baldi; Drahomir Aujesky; Daniel Hayoz; Rolf P. Engelberger; Thomas Kaeslin; Wolfgang Korte; Robert Escher; Marc Husmann; Annette Mollet; Thomas D. Szucs; Nils Kucher

doi:10.1055/s-0039-1698770

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2019; 45(08): 851-858
DOI: 10.1055/s-0039-1698770

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Venous Thromboembolism and Renal Impairment: Insights from the SWIss Venous ThromboEmbolism Registry (SWIVTER)

David Spirk

¹Institute of Pharmacology, University of Bern, Bern, Switzerland

,

Tim Sebastian

²Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

,

Martin Banyai

²Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

,

Jürg H. Beer

³Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland

,

Lucia Mazzolai

⁴Clinic of Angiology, University Hospital Lausanne, Lausanne, Switzerland

,

Thomas Baldi

⁵Department of Internal Medicine, University Hospital Basel, Basel, Switzerland

,

Drahomir Aujesky

⁶Division of General Internal Medicine, Bern University Hospital, Bern, Switzerland

,

Daniel Hayoz

⁷Department of Internal Medicine, Cantonal Hospital Fribourg, Villars-sur-Glâne, Switzerland

,

Rolf P. Engelberger

⁷Department of Internal Medicine, Cantonal Hospital Fribourg, Villars-sur-Glâne, Switzerland

,

Thomas Kaeslin

⁸Department of Internal Medicine, Cantonal Hospital Obwalden, Sarnen, Switzerland

,

Wolfgang Korte

⁹Department of Internal Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

,

Robert Escher

¹⁰Department of Internal Medicine, Regional Hospital Burgdorf, Burgdorf, Switzerland

,

Marc Husmann

²Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

,

Annette Mollet

¹¹European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland

,

Thomas D. Szucs

¹¹European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland

,

Nils Kucher

²Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

› Institutsangaben

Abstract

Renal impairment (RI) has increased substantially over the last decades. In the absence of data from confirmatory research, real-life data on anticoagulation treatment and clinical outcomes of venous thromboembolism (VTE) in patients with RI are needed. In the SWIss Venous ThromboEmbolism Registry (SWIVTER), 2,062 consecutive patients with objectively confirmed VTE were enrolled. In the present analysis, we compared characteristics, initial and maintenance anticoagulation, and adjusted 90-day clinical outcomes of those with (defined as estimated creatinine clearance < 30 mL/min) and without severe RI. Overall, 240 (12%) patients had severe RI; they were older, and more frequently had chronic and acute comorbidities. VTE severity was similar between patients with and without severe RI. Initial anticoagulation in patients with severe RI was more often performed with unfractionated heparin (44 vs. 24%), and less often with low-molecular-weight heparin (LMWH) (52 vs. 61%) and direct oral anticoagulants (DOACs; 4 vs. 12%). Maintenance anticoagulation in patients with severe RI was more frequently managed with vitamin K antagonists (70 vs. 60%) and less frequently with DOAC (12 vs. 21%). Severe RI was associated with increased risk of 90-day mortality (9.2 vs. 4.2%, hazard ratio [HR]: 2.27, 95% confidence interval [CI]: 1.41–3.65), but with similar risk of recurrent VTE (3.3 vs. 2.8%, HR: 1.19, 95% CI: 0.57–2.52) and major bleeding (2.1 vs. 2.0%, HR: 1.05, 95% CI: 0.41–2.68). In patients with severe RI, the use of LMWH versus any other treatment was associated with reduced mortality (HR: 0.37; 95% CI: 0.14–0.94; p = 0.036) and similar rate of major bleeding (HR: 0.59, 95% CI: 0.17–2.00; p = 0.39). Acute or chronic comorbidities rather than VTE severity or recurrence may explain increased early mortality in patients with severe RI. The higher rate of VTE recurrence, specifically fatal events, than major bleeding reinforces the need for effective anticoagulation in VTE patients with severe RI.

Keywords

anticoagulation - mortality - renal impairment - venous thromboembolism

Volltext

Referenzen

References
1 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12 (10) 1580-1590
2 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e496S
3 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
4 Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19 (01) 135-140
5 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
6 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (09) 673-684
7 Spinler SA, Mahaffey KW, Gallup D. , et al; SYNERGY Trial Investigators. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol 2010; 144 (01) 36-41
8 Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. ; ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146 (01) 33-41
9 Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 2016; 149 (04) 951-959
10 Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials. Chest 2016; 149 (06) 1516-1524
11 Rattazzi M, Villalta S, De Lucchi L. , et al. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence. Thromb Res 2017; 160: 32-37
12 Parikh AM, Spencer FA, Lessard D. , et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis 2011; 58 (05) 746-755
13 Spirk D, Aujesky D, Stuck AK. , et al. Clinical outcomes of venous thromboembolism in patients with and without cancer: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Semin Thromb Hemost 2016; 42 (06) 642-649
14 Alatri A, Mazzolai L, Kucher N. , et al. The modified Ottawa Score and clinical events in hospitalized patients with cancer-associated thrombosis from the Swiss VTE Registry. Semin Thromb Hemost 2017; 43 (08) 871-876
15 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
16 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
17 Fihn SD, McDonell M, Martin D. , et al; Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993; 118 (07) 511-520
18 Anderson Jr FA, Wheeler HB, Goldberg RJ. , et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151 (05) 933-938
19 Falgá C, Capdevila JA, Soler S. , et al; RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98 (04) 771-776
20 Böttger B, Wehling M, Bauersachs RM. , et al. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients. Thromb Res 2014; 134 (05) 1014-1019
21 Puymirat E, Aïssaoui N, Collet JP. , et al. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol 2013; 166 (01) 106-110
22 Trujillo-Santos J, Schellong S, Falga C. , et al; RIETE Investigators. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med 2013; 126 (05) 425-434.e1
23 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
24 Siontis KC, Zhang X, Eckard A. , et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138 (15) 1519-1529
25 Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018; 44 (04) 353-363